1 1

Cagrilintide (10mg)

Cagrilintide (10mg)

$95.00 USD
$95.00 USD
Sale Sold out
Shipping calculated at checkout.

Overview

Cagrilintide is a long-acting synthetic analogue of amylin, a peptide hormone naturally secreted by pancreatic beta cells together with insulin. Amylin plays a vital role in controlling appetite, slowing stomach emptying, and regulating glucose metabolism after meals. Cagrilintide has been modified to resist enzymatic breakdown, extending its duration of activity. Early research indicates that this compound may support body weight regulation, improve glycemic stability, and work in combination with other metabolic agents such as semaglutide for enhanced outcomes.

In laboratory and early human studies, Cagrilintide has demonstrated the ability to reduce food intake and promote feelings of fullness, leading to measurable reductions in body weight. It has also shown potential to improve overall metabolic health by modulating hormonal signals that influence hunger and glucose balance. While results are promising, further controlled research is required to confirm its safety profile, long-term efficacy, and therapeutic applications.

 

COA

BPC-157 Test Results

Third-Party Testing

PubChem Information

https://pubchem.ncbi.nlm.nih.gov/compound/171397054

View full details

What is Cagrilintide?

  • Mechanism of Action:

    • Functions as an amylin receptor agonist, imitating the natural effects of amylin in appetite and energy regulation.
    • Delays gastric emptying, leading to prolonged satiety and reduced post-meal blood sugar elevations.
    • Activates amylin receptors within the hypothalamus and brainstem, promoting central satiety signaling and lowering food motivation.
    • Suppresses glucagon secretion from pancreatic alpha cells, decreasing hepatic glucose production and fat storage.
    • Exhibits extended stability and
      bioavailability.
    • In combination with GLP-1 receptor agonists such as semaglutide, produces complementary metabolic effects, amplifying appetite suppression.

  • Preclinical Studies:

    • Cagrilintide and related amylin analogues have been shown to decrease food intake, improve insulin sensitivity, and reduce circulating lipids.
    • Studies combining amylin and leptin analogues revealed a synergistic effect, resulting in greater weight reduction, improved body composition, and enhanced lipid and glucose metabolism.

    Investigational studies are evaluating:

    • Obesity and metabolic syndrome
    • Type 2 diabetes mellitus
    • Cardiovascular and lipid disorders
    • Non-alcoholic fatty liver disease and alcohol-related liver damage
    • Neurodegenerative conditions, including exploratory interest in Alzheimer’s disease

    Overall findings support its potential role in metabolic regulation, energy balance, and long-term weight management, though further clinical validation is needed.

  • Intended Use:

    • The information provided on this site is intended exclusively for educational and research purposes and should not be interpreted as medical guidance.
    • Research compounds, including Cagrilintide, are designed solely for laboratory investigation by qualified professionals and are not intended for human use or consumption.
    • The statements presented here have not been evaluated by the U.S. Food and Drug Administration, and the products discussed are not intended to diagnose, treat, cure, or prevent any disease.